Clinical Trial Detail

NCT ID NCT03881735
Title Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Roswell Park Cancer Institute
Indications

acute myeloid leukemia

Therapies

Enasidenib

Age Groups: adult senior

Additional content available in CKB BOOST